Baseline characteristics and laboratory determinations for patients with dual or triple antiplatelet therapy.

<p>Values were presented as number (%) and mean±SD. CK, creatine kinase.</p

Changes of PA in dual and triple antiplatelet therapy.

<p>Before treatment PA was performed before clinical treatment, after treatment PA was performed after 7 days under intensive therapy (^*Triple-After treatment vs. Dual-After treatment, P = 0.002).</p

Baseline angiographic and PCI results.

<p>Values were presented as number (%) and mean±SD. PCI, percutaneous coronary intervention, LMWH, low molecular weight heparin.</p

ROC curve analysis in PA and ischemic events.

<p>PA, platelet aggregation; AUC, area under the curve; CI, confidence interval. Cut off value was calculated by determining the smallest distance between receiver operating characteristic curve and upper left corner of the graph.</p

Baseline clinical characteristics.

<p>Values were presented as number (%) and mean±SD. ACEI, Angiotensin converting enzyme inhibitor; TnT, troponin T, CRP, C-reactive protein.</p

Time distribution of primary events.

<p>Blue curve indicated cumulative hazard of primary events. Before the 15^th day, 22 primary events developed, cumulative hazard was 0.17, number of total primary events was 41 in one year, cumulative hazard was 0.34.</p